Tabuk Pharmaceuticals inks deal to commercialize Moderna COVID-19 vaccine in Saudi Arabia

Tabuk Pharmaceuticals inks deal to commercialize Moderna COVID-19 vaccine in Saudi Arabia

Saudi Gazette report JEDDAH “” Tabuk Pharmaceutical Manufacturing Company, a leading Saudi pharmaceuticals company, has signed an agreement with Moderna Inc, a US-based biotechnology company, to commercialize the Moderna COVID-19 vaccine and future variant-specific booster candidates in Saudi Arabia. The announcement of the agreement was made by the US company in a tweet on Friday, saying: "This morning we announced an agreement with @TabukPharma to commercialize the Moderna COVID-19 vaccine and future variant-specific booster candidates in Saudi Arabia.“ Under the terms of this agreement, Tabuk Pharmaceuticals , a fully owned subsidiary of Astra Industrial Group, will hold the marketing authorization for the Moderna COVID-19 vaccine in Saudi Arabia. Beyond the Moderna COVID-19 vaccine and Moderna's updated variant booster candidates, the agreement also gives Tabuk the possibility to discuss opportunities to distribute other Moderna mRNA products if authorized in the future. Commenting on the agreement, Stéphane Bancel, chief executive officer of Moderna said: "We appreciate the collaboration of Tabuk Pharmaceuticals in this new partnership in Saudi Arabia. "It is thanks to partnerships such as these that we are able to expand access to our vaccine globally, and we hope it will support the availability of our COVID-19 vaccine for the benefit